Related Experiment Video
Updated: Sep 20, 2025
06:58
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
5.1K
SCN1A-Related Epilepsy: Novel Mutations and Rare Phenotypes
Rui Ma1,2, Yiran Duan1,2, Liping Zhang3
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Frontiers in Molecular Neuroscience
|June 6, 2022
Summary
This study identifies 12 new SCN1A gene variants in epilepsy patients, expanding knowledge of SCN1A-related epilepsy genotypes and phenotypes. The findings detail clinical characteristics for these novel variants.
Area of Science:
- Genetics
- Neurology
- Epilepsy Research
Background:
- Sodium voltage-gated channel alpha subunit 1 (SCN1A) gene mutations are linked to various epilepsy types.
- Expanding the understanding of SCN1A genotypes and phenotypes is crucial for accurate diagnosis and treatment.
Purpose of the Study:
- To broaden the known spectrum of genotypes and phenotypes associated with SCN1A-related epilepsy.
- To characterize the clinical presentation of patients with newly identified SCN1A variants.
Main Methods:
- Retrospective analysis of clinical and genetic data from 22 epilepsy patients.
- Identification of SCN1A mutations using next-generation sequencing.
Main Results:
- Twenty-two SCN1A variants were identified, including 12 novel mutations.
- Median age of seizure onset was 6 months; 16 patients had Dravet syndrome.
- Fourteen patients exhibited global developmental delay/intellectual disability.
Conclusions:
- This study significantly expands the genotypic and phenotypic landscape of SCN1A-related epilepsies.
- The clinical features of patients carrying 12 previously unreported SCN1A variants are now described, aiding future research and clinical practice.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
297
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
297
01:13Seizures: Classification
623
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
623
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
465
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
465
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
689
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
689
01:08Antiepileptic Drugs: Sodium Channel Blockers
969
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
969
01:05Single Nucleotide Polymorphisms-SNPs
16.0K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.0K